Oppenheimer analyst Leland Gershell maintained a Buy rating on Milestone Pharmaceuticals (MIST) today and set a price target of $18.00. The company’s shares closed last Friday at $8.55.
According to TipRanks.com, Gershell is a 5-star analyst with an average return of 12.5% and a 48.9% success rate. Gershell covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Corbus Pharmaceuticals, and Miragen Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Milestone Pharmaceuticals with a $13.25 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.01 and a one-year low of $1.69. Currently, Milestone Pharmaceuticals has an average volume of 5.28M.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
Read More on MIST:
